Bimekizumab is Coming… in 3rd Place Nearly two dozen bimekizumab abstracts will be featured at #ACR23 and it recently received authorization in Europe and the US for psoriasis. https://t.co/i2ptDnGr4a https://t.co/rZC6IORm5E